Jupiter Neurosciences reported deepening Q1 FY2026 losses and accelerated cash burn, driven by larger net loss amid Nugevia supplement launch revenue and ongoing CNS pipeline development, while maintaining strong gross margins on modest sales.
Key takeaways
Revenue reached $18.7K from Nugevia supplement sales, marking initial commercialization of JOTROL™ resveratrol platform.
Gross profit was $14.3K, delivering 76.6% gross margin on premium wellness products.
Operating income was -$2.0M, a 27.6% worsening from -$1.5M prior year due to expense pressures.
Net income was -$2.1M, down 34.9% from -$1.5M, reflecting increased interest on Convertible Notes.
Diluted EPS was -$0.06 versus -$0.05 prior year, a -20.0% decline.
Full analysis
Nugevia Launch Generates Initial Revenue Amid Loss Expansion
Operating and Net Losses Widen on Fixed Costs and Financing